Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.
Cardiac amyloidosis
heart failure
transthyretin
Journal
Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
02
07
2021
revised:
25
09
2021
accepted:
30
09
2021
pubmed:
12
10
2021
medline:
4
5
2022
entrez:
11
10
2021
Statut:
ppublish
Résumé
The V122I variant in transthyretin (TTR) is the most common amyloidogenic mutation worldwide. The aim of this study is to describe the cardiac phenotype and risk for adverse cardiovascular outcomes of young V122I TTR carriers in the general population. TTR genotypes were extracted from whole-exome sequence data in participants of the Dallas Heart Study. Participants with African ancestry, available V122I TTR genotypes (N = 1818) and either cardiac magnetic resonance imaging (n = 1364) or long-term follow-up (n = 1532) were included. The prevalence of V122I TTR carriers (45 ± 10 years) was 3.2% (n/N = 59/1818). The V122I TTR carriers had higher baseline left ventricular wall thickness (8.52 ± 1.82 vs 8.21 ± 1.62 mm, adjusted P = .038) than noncarriers, but no differences in other cardiac magnetic resonance imaging measures (P > .05 for all). Although carrier status was not associated with amino terminal pro-B-type natriuretic peptide (NT-proBNP) at baseline (P = .79), V122I TTR carriers had a greater increase in NT-proBNP on follow-up than noncarriers (median 28.5 pg/mL, interquartile range 11.4-104.1 pg/mL vs median 15.9 pg/mL, interquartile range 0.0-43.0 pg/mL, adjusted P = .018). V122I TTR carriers were at a higher adjusted risk of heart failure (hazard ratio 3.82, 95% confidence interval 1.80-8.13, P < .001), cardiovascular death (hazard ratio 2.65, 95% confidence interval 1.14-6.15, P = .023), and all-cause mortality (hazard ratio 1.95, 95% confidence interval 1.08-3.51, P = .026) in comparison with noncarriers. V122I TTR carrier status was associated with a greater increase in NT-proBNP, slightly greater left ventricular wall thickness, and a higher risk for heart failure, cardiovascular death, and all-cause mortality. These findings suggest the need to develop amyloidosis screening strategies for V122I TTR carriers.
Sections du résumé
BACKGROUND
The V122I variant in transthyretin (TTR) is the most common amyloidogenic mutation worldwide. The aim of this study is to describe the cardiac phenotype and risk for adverse cardiovascular outcomes of young V122I TTR carriers in the general population.
METHODS AND RESULTS
TTR genotypes were extracted from whole-exome sequence data in participants of the Dallas Heart Study. Participants with African ancestry, available V122I TTR genotypes (N = 1818) and either cardiac magnetic resonance imaging (n = 1364) or long-term follow-up (n = 1532) were included. The prevalence of V122I TTR carriers (45 ± 10 years) was 3.2% (n/N = 59/1818). The V122I TTR carriers had higher baseline left ventricular wall thickness (8.52 ± 1.82 vs 8.21 ± 1.62 mm, adjusted P = .038) than noncarriers, but no differences in other cardiac magnetic resonance imaging measures (P > .05 for all). Although carrier status was not associated with amino terminal pro-B-type natriuretic peptide (NT-proBNP) at baseline (P = .79), V122I TTR carriers had a greater increase in NT-proBNP on follow-up than noncarriers (median 28.5 pg/mL, interquartile range 11.4-104.1 pg/mL vs median 15.9 pg/mL, interquartile range 0.0-43.0 pg/mL, adjusted P = .018). V122I TTR carriers were at a higher adjusted risk of heart failure (hazard ratio 3.82, 95% confidence interval 1.80-8.13, P < .001), cardiovascular death (hazard ratio 2.65, 95% confidence interval 1.14-6.15, P = .023), and all-cause mortality (hazard ratio 1.95, 95% confidence interval 1.08-3.51, P = .026) in comparison with noncarriers.
CONCLUSIONS
V122I TTR carrier status was associated with a greater increase in NT-proBNP, slightly greater left ventricular wall thickness, and a higher risk for heart failure, cardiovascular death, and all-cause mortality. These findings suggest the need to develop amyloidosis screening strategies for V122I TTR carriers.
Identifiants
pubmed: 34634447
pii: S1071-9164(21)00400-0
doi: 10.1016/j.cardfail.2021.09.015
pmc: PMC8923911
mid: NIHMS1748368
pii:
doi:
Substances chimiques
Prealbumin
0
TTR protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
403-414Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001105
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
N Engl J Med. 2015 Jan 1;372(1):21-9
pubmed: 25551524
Circulation. 2016 Jun 14;133(24):2404-12
pubmed: 27143678
Int J Cardiol. 2019 Oct 15;293:10-16
pubmed: 31327521
Circ Heart Fail. 2017 Aug;10(8):
pubmed: 28775115
J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20
pubmed: 27585505
Hum Mol Genet. 2005 Feb 15;14(4):543-53
pubmed: 15649951
JAMA Cardiol. 2020 Dec 23;:
pubmed: 33355618
Amyloid. 2015;22(3):171-4
pubmed: 26123279
JAMA. 2010 Dec 8;304(22):2494-502
pubmed: 21078811
JAMA. 2019 Dec 10;322(22):2191-2202
pubmed: 31821430
Science. 2016 Dec 23;354(6319):
pubmed: 28008009
Hypertension. 2005 Jul;46(1):124-9
pubmed: 15939807
J Card Fail. 2019 Nov;25(11):e1-e39
pubmed: 31473268
Int J Cardiol. 2016 Jul 1;214:477-81
pubmed: 27093686
N Engl J Med. 2018 Sep 13;379(11):1007-1016
pubmed: 30145929
Circulation. 2017 May 30;135(22):2119-2132
pubmed: 28360032
Eur Heart J. 2018 Aug 7;39(30):2799-2806
pubmed: 29048471
Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14943-8
pubmed: 11752443
Gigascience. 2015 Feb 25;4:7
pubmed: 25722852
JACC Cardiovasc Imaging. 2010 Feb;3(2):155-64
pubmed: 20159642
Circ Cardiovasc Imaging. 2013 Mar 1;6(2):195-201
pubmed: 23400849
Circulation. 2019 Jul 2;140(1):16-26
pubmed: 31109193
J Am Coll Cardiol. 2019 Jul 23;74(3):285-295
pubmed: 30885685
PLoS One. 2017 Apr 6;12(4):e0173086
pubmed: 28384285
J Am Coll Cardiol. 2016 Jul 12;68(2):161-72
pubmed: 27386769
Am Heart J. 2009 Apr;157(4):746-53.e2
pubmed: 19332205